Biotechnology-focused investment firm Baker Bros. Advisors increased its position in Insmed Incorporated. According to a quarterly filing with the SEC, the firm acquired an additional 1.38 million shares, bringing its total to 8.80 million. It's important to note that this disclosure reflects trades made between April 1 and June 30, 2026, and was publicly filed on August 14.
Subsequent to this reporting period, Insmed has seen positive developments. On August 6, the company reported strong second-quarter financial results, driven by its lung-disease drug, BRINSUPRI. [3, 4] Later, on August 24, Japanese regulators approved BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis. [1, 4] The value of Baker Bros.' holding was reported as $937.84 million at the end of June.